Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.
The aim of this study was to characterize the pharmacodynamic, pharmacokinetic, and adverse-effect profiles of retigabine (RTG) in combination with carbamazepine (CBZ), lamotrigine (LTG), and valproate (VPA). The isobolographic analysis for parallel and nonparallel dose-response effects was used in the mouse maximal electroshock seizure (MES) model for evaluation of pharmacodynamic interaction. Potential adverse-effect profiles of interactions of RTG with CBZ, LTG, and VPA at the fixed ratio of 1:1 in the MES test were evaluated in the chimney (motor performance), passive avoidance (long-term memory), and grip strength (muscular strength) tests. Free plasma and total brain concentrations of CBZ, LTG, and VPA were determined by immunofluorescence and chromatography to assess pharmacokinetic interaction. In the MES model, RTG administered singly had its dose-response relationship curve (DRRC) parallel to that for VPA and nonparallel to that for CBZ and LTG. With isobolography for parallel DRRCs, the combination of RTG with VPA at fixed ratios of 1:3, 1:1, and 3:1 exerted supraadditive (synergistic) interaction. Isobolography for nonparallel DRRCs revealed that the combinations of RTG with CBZ and LTG at the fixed ratio of 1:1 produced additive interaction. In all combinations, neither motor coordination, long-term memory, nor muscular strength were affected. Only the combination of RTG with VPA at the fixed ratio of 3:1 was complicated by a pharmacokinetic increase in both free plasma and total brain VPA concentrations. All remaining combinations of RTG with VPA, CBZ, and LTG were pharmacodynamic in nature. RTG synergistically interacted with VPA and exerted additive interaction with CBZ and LTG in the mouse MES model.
Luszczki
Jarogniew J
JJ
Department of Pathophysiology, Medical University, Lublin, Poland. jarogniew.luszczki@gmail.com
Wu
Jim Z
JZ
Raszewski
Grzegorz
G
Czuczwar
Stanislaw J
SJ
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D002219:Carbamates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002220:Carbamazepine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004597:Electroshock; D007274:Injections, Intraperitoneal; D000077213:Lamotrigine; D008297:Male; D008568:Memory / Q000187:drug effects; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D053580:Muscle Strength / Q000187:drug effects; D010655:Phenylenediamines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects; D012640:Seizures / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D014227:Triazines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014635:Valproic Acid / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; D014227:Triazines; C101866:ezogabine; D002220:Carbamazepine; D014635:Valproic Acid; D000077213:Lamotrigine
Epilepsia. 2003 Aug;44(8):1003-13
12887431
Epilepsia. 2007 Apr;48(4):806-15
17284299
Epilepsia. 2002;43 Suppl 5:86-95
12121301
Drug Metab Dispos. 1999 May;27(5):605-12
10220490
Epilepsia. 2000 Nov;41(11):1364-74
11077449
Mol Pharmacol. 2000 Aug;58(2):253-62
10908292
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):529-38
17204358
Pharmacol Ther. 2005 Apr;106(1):1-18
15781119
J Clin Pharm Ther. 1993 Jun;18(3):191-7
8345004
Acta Neurol Scand. 1995 Mar;91(3):200-2
7793236
J Clin Pharmacol. 2002 Feb;42(2):175-82
11831540
Neurology. 2007 Apr 10;68(15):1197-204
17420403
Pharmacol Res. 2000 Dec;42(6):553-7
11058408
J Pharmacol Exp Ther. 2004 Sep;310(3):981-6
15175417
Clin Pharmacol Ther. 1980 Oct;28(4):486-92
6773716
Neurosci Lett. 1995 Aug 4;195(2):77-80
7478272
Clin Pharmacol Ther. 2003 Jan;73(1):61-70
12545144
J Pharmacol Exp Ther. 2006 Oct;319(1):1-7
16670349
J Pharmacol Exp Ther. 1949 Jun;96(2):99-113
18152921
Epilepsy Res. 2003 Feb;53(1-2):1-17
12576163
Neurotherapeutics. 2007 Jan;4(1):149-54
17199031
Nat Genet. 1998 Jan;18(1):53-5
9425900
Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):33-9
9933148
Epilepsy Res. 1999 Jun;35(2):99-107
10372563
J Clin Pharm Ther. 1995 Aug;20(4):215-9
8557785
Seizure. 2002 Sep;11(6):349-51
12160660
Epilepsia. 2007 Mar;48(3):412-34
17346245
Epilepsia. 1979 Jun;20(3):303-11
376307
Arch Neurol. 1983 Dec;40(13):797-802
6416232
Seizure. 2000 Oct;9(7):464-8
11034869
Pharmacol Rev. 1990 Sep;42(3):223-86
2217531
Curr Top Med Chem. 2005;5(1):3-14
15638774
Epilepsy Res. 2004 Jul-Aug;60(2-3):77-159
15540387
Trends Pharmacol Sci. 2008 Apr;29(4):186-91
18353445
Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):330-6
11284448
Epilepsy Res. 1997 Mar;26(3):423-32
9127723
Lancet. 1998 Mar 28;351(9107):958-9
9734949
Acta Neurol Scand Suppl. 1995;162:31-4
7495187
Ther Drug Monit. 1985;7(4):387-90
3936236
Pharmacol Rev. 1989 Jun;41(2):93-141
2692037
Neurosci Lett. 2000 Mar 17;282(1-2):73-6
10713399
Lancet. 1994 Jun 25;343(8913):1650
7911963
CNS Drugs. 2002;16(10):669-94
12269861
Epilepsy Res. 1991 Mar;8(2):79-94
2065646
Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):51-64
16972063
Epilepsia. 2000 Jan;41(1):28-33
10643920
Naunyn Schmiedebergs Arch Pharmacol. 2006 May;373(2):169-81
16604339
Epilepsy Res. 2001 May;44(2-3):155-65
11325571
Eur J Pharmacol. 2003 Mar 19;464(2-3):95-100
12620500
Eur J Pharmacol. 1996 May 15;303(3):163-9
8813562
Nature. 1986 Jun 26-Jul 2;321(6073):864-6
3724846
Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):105-14
17333129
Epilepsia. 1999 Aug;40(8):1141-6
10448829
J Pharmacol Exp Ther. 1988 Dec;247(3):1128-32
3144596
Pharmacol Rev. 1995 Jun;47(2):331-85
7568331
Eur J Pharmacol. 1999 Dec 15;386(2-3):165-71
10618466
Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):483-92
18566800
Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):434-46
14985937
Epilepsy Res. 2006 Jun;69(3):183-272
16835945
Neurochem Res. 2005 Dec;30(12):1557-65
16362775
Epilepsia. 2004 May;45(5):424-35
15101823
J Clin Pharmacol. 1997 Dec;37(12):1160-7
9506012
Arzneimittelforschung. 1953 Jun;3(6):285-90
13081480
Epilepsy Res. 2000 Jan;38(1):53-66
10604606
Ther Drug Monit. 1997 Apr;19(2):153-9
9108642
Epilepsy Res. 1988 May-Jun;2(3):145-81
3058469
Neuropsychopharmacology. 2005 May;30(5):958-73
15525996
Epilepsy Res. 2003 Sep;56(1):27-42
14529951
Pharmacol Ther. 2007 Jan;113(1):197-209
17079019
Arzneimittelforschung. 2000 Dec;50(12):1063-70
11190770
Epilepsia. 2003 Apr;44(4):489-99
12680997
Neurobehav Toxicol. 1979 Fall;1(3):233-6
551317
Eur J Pharmacol. 1997 Oct 8;336(2-3):243-9
9384239
Nat Genet. 1998 Jan;18(1):25-9
9425895
Epilepsy Res. 1996 Apr;23(3):211-23
8739124
N Engl J Med. 2000 Feb 3;342(5):314-9
10660394